Armotraz 1 mg – Composition, Uses and Medicine Enquiries
Product Overview
Armotraz 1 mg is listed under the anticancer category and belongs to the aromatase inhibitor class. Its active composition is Anastrozole 1 mg. It is associated with hormone receptor-positive breast cancer in postmenopausal women.
Anastrozole reduces estrogen synthesis by inhibiting the aromatase enzyme. Suitability depends on the diagnosis, approved product labeling, clinical history and specialist assessment. This information is provided for education and product identification and is not a recommendation to begin treatment.
The supplied spreadsheet contains a note to verify the product title and strength against the actual pack before publication.
Composition and Strength
| Product Name | Generic Name | Brand Name | Strength |
|---|---|---|---|
| Armotraz 1 mg | Anastrozole | Armotraz | 1 mg |
Therapeutic Category and Indication
- Therapeutic Category: Anticancer
- Medicine Class: Aromatase inhibitor
- Associated Indication: Hormone receptor-positive breast cancer in postmenopausal women
The exact brand-specific approval and indication should be checked against the manufacturer’s approved product information before publication.
Administration Information
The supplied information describes oral administration. Follow the exact prescribed route, dose and schedule. Do not change, share or discontinue treatment without consulting the treating oncologist. Refer to the manufacturer’s instructions for product-specific administration information.
Product Presentation and Availability
- Product: Armotraz 1 mg
- Active Composition: Anastrozole 1 mg
- Listed Manufacturer/Marketer: Cipla Ltd — attribution requires independent verification
- Dosage Form and Pack Size: Verify from the actual manufacturer pack
The current pack size, labeling, batch details and expiry should be independently checked. No particular packaging, stock or delivery is promised by Medinglobal.
Prescription and Patient Safety
A qualified clinician should confirm whether this exact brand, strength and formulation are appropriate before any prescription or treatment decision. Suitability depends on the patient’s diagnosis, clinical history, other medicines and the applicable prescribing information.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal receives enquiries about Armotraz 1 mg and may coordinate requests for product information with independent, appropriately authorized pharmaceutical providers.
Medinglobal is not the manufacturer, direct seller, dispensing pharmacy or exporter of this product. Any permitted transaction, prescription check, destination-country assessment, supply terms and supporting documentation are handled by the relevant authorized provider. An enquiry does not guarantee availability or supply.
How to Submit an Armotraz 1 mg Enquiry
Submit the brand name, strength, formulation, requested quantity and destination country through Medinglobal’s medicine enquiry channel. Include a valid prescription or institutional documents when required.
An appropriately authorized independent provider must independently confirm product identity, applicable legal requirements and any commercial terms.
Frequently Asked Questions
What is Armotraz 1 mg used for?
It is associated with hormone receptor-positive breast cancer in postmenopausal women, subject to the exact approved product label and medical assessment.
What does Armotraz 1 mg contain?
It contains Anastrozole 1 mg. Confirm the final composition against the manufacturer’s pack.
How is Armotraz 1 mg administered?
The supplied information describes oral administration. Follow the exact instructions provided by the treating clinician and manufacturer.
Can I request product information through Medinglobal?
Yes. Medinglobal can receive a coordination enquiry, but supply is neither guaranteed nor directly undertaken by Medinglobal.




Reviews
There are no reviews yet.